drugset / Trial / NCT00115427

Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

NCT00115427 ↗

Phase 1 Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.

Timeline

Start
2003-03
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Liatermin Protein / enzyme biologic 15 mg Other

Indications